$213 Million

Fusion Pharmaceuticals

Initial Public Offering

Bookrunner, June 2020

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. The Company has developed a Targeted Alpha Therapies, or TAT, platform together with its proprietary Fast-Clear linker technology to enable it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. The Company’s lead product candidate, FPI-1434, utilizes Fast-Clear linker technology to connect a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor, or IGF-1R, with the alpha emitting isotope actinium-225, or 225Ac. The Company’s second product candidate, FPI-1966, uses vofatamab as its targeting molecule to target and deliver 225Ac to tumors expressing FGFR3, a protein that is overexpressed in head and neck and bladder cancers.

More Like This

Jul 2020
$144 Million

Initial Public Offering

Sole Bookrunner

View Details
Jun 2020
$244 Million

Initial Public Offering

Bookrunner

View Details
Jun 2020
$253 Million

Initial Public Offering

Bookrunner

View Details